Fig. 2.

a SF-36 PCS over time and b mean change in SF-36 PCS from baseline to week 24. c SF-36 MCS over time and d mean change in SF-36 MCS from baseline to week 24. p values of comparison between MTX dosage groups at week 24 (ANCOVA) in a and c. **p < 0.001, comparison between scores at baseline and at week 24 (t test) for each MTX dosage group in b and d. Reprinted from the 2014 ACR/ARHP Annual Meeting held November 14–19, 2014. The American College of Rheumatology does not guarantee, warrant, or endorse any commercial products or services